Search Within

Chau Dang

Formats
  1. Journal Article (132)
  2. Meeting Abstract (122)
  3. Guidelines (8)
  4. Book Section (4)
  5. Review (3)
  6. Book Whole (1)
  7. Editorial (1)
  8. Miscellaneous (1)
  9. Research Letter (1)
Groups
  1. Breast Medicine Service (273)
  2. Department of Medicine (273)
  3. Solid Tumor Oncology Division (273)
  4. Survivorship Research (273)
  5. Population Sciences Research Program (119)
  6. Epidemiology and Biostatistics (93)

More Groups

People
  1. Clifford Hudis (111)
  2. Larry Norton (76)
  3. Richard Steingart (49)
  4. Anthony Yu (46)
  5. Shanu Modi (42)
  6. Sujata Patil (41)

More People

Years
  1. 2025 (4)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (18)
  5. 2021 (12)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (68)
  2. Cancer Research (42)
  3. Breast Cancer Research and Treatment (23)
  4. Annals of Oncology (10)
  5. Clinical Breast Cancer (7)
  6. Clinical Cancer Research (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (70)
  2. American Association for Cancer Research (50)
  3. Springer (33)
  4. Oxford University Press (22)
  5. Elsevier Inc. (16)
  6. American Medical Association (11)

More Publishers

Results (273)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S. B.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; Comen, E. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Tolaney, S. M.; Barry, W. T.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. K.; Albain, K. S.; Rugo, H. S.; Ellis, M.; Shapira, I.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Chemotherapy-related amenorrhea on adjuvant paclitaxel-trastuzumab (APT trial)
    Meeting Abstract

    Ruddy, K. J.; Tolaney, S. M.; Guo, H.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. K.; Albain, K. S.; Rugo, H. S.; Ellis, M. J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Cardiac safety of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as (neo) adjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (EBC): Final data from TDM4874g
    Meeting Abstract

    Krop, I. E.; Suter, T. M.; Dirix, L.; Romieu, G.; Zamagni, C.; Citron, M. L.; Campone, M.; Dang, C. T.; Xu, N.; Smitt, M.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Morris, P. G.; Lake, D. E.; D'Andrea, G. M.; Dickler, M. N.; Gilewski, T. A.; Dang, C. T.; McArthur, H. L.; Bromberg, J. F.; Goldfarb, S. B.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Meeting Abstract

    Iyengar, N. M.; Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Morris, P. G.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R. J.; Steingart, R.; Oeffinger, K. C.; Lin, N. U.; Moy, B.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Impact of trastuzumab-induced cardiotoxicity and cubsequent trastuzumab interruption on breast cancer outcome
    Meeting Abstract

    Yu, A. F.; Yadav, N. U.; Manrique, C. R.; Thaler, H. T.; Hudis, C. A.; Dang, C. T.; Steingart, R. M.
    Circulation (2013)

    Fulltext@MSK | Save
  • Dual targeting of human epidermal growth factor receptor 2 (HER2) in neoadjuvant trials for operable HER2 positive (HER2+) disease
    Journal Article

    Jhaveri, K.; Dang, C.
    Current Breast Cancer Reports (2013)

    Fulltext@MSK | Save
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer
    Journal Article

    Morris, P. G.; Iyengar, N. M.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R.; Steingart, R.; Oeffinger, K. C.; Lin, N.; Moy, B.; more...
    Cancer (2013)

    Fulltext@MSK | Save